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Abstract
Carbapenemase-producing Enterobacterales (CPE) pose an increasing threat to patient safety and healthcare systems globally.
We present molecular epidemiology of CPE in Finland during 2012–2018 with detailed characteristics of CPE strains causing
clusters during the same time period. All Finnish clinical microbiology laboratories send Enterobacterales isolates with reduced
susceptibility to carbapenems or isolates producing carbapenemase to the reference laboratory for further characterization by
whole genome sequencing (WGS). In total, 231 CPE strains from 202 patients were identified during 2012–2018. Of the strains,
59% were found by screening and 32% from clinical specimens, the latter were most commonly urine. Travel and/or hospital-
ization history abroad was reported for 108/171 strains (63%). The most common species were Klebsiella pneumoniae (45%),
Escherichia coli (40%), and Citrobacter freundii (6%), and the most common carbapenemase genes blaNDM-like (35%), blaOXA-
48-like (33%), and blaKPC-like (31%). During 2012–2018, the annual number of CPE strains increased from 9 to 70 and different
sequence types from 7 to 33, and blaOXA-48-like genes became the most prevalent. Of the clusters, 3/8 were linked to traveling or
hospitalization abroad and 5/8 were caused by K. pneumoniae clone clonal complex 258. Most of the clusters were caused by
K. pneumoniae producing KPC. High variety among different sequence types indicates that majority of CPE cases detected in
Finland are likely imported from foreign countries. Nearly one-third of the cases are not found by screening suggesting that there
is hidden transmission occurring in the healthcare settings.
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Introduction
Carbapenem-resistant Enterobacterales are one of the most
significant increasing health threats globally according to the
WHO [1]. In addition to carbapenemase genes, carbapenem-
producing Enterobacterales (CPE) have typically collected
other resistance genes and are often extensively drug-resistant
or even pan-drug resistant, limiting treatment options [2] and
leading subsequently to high fatality [3]. Transmission of CPE
primarily occurs in hospitals and other healthcare facilities [4].
Transmission of the K. pneumoniae clonal complex (CC) 258
including, sequence types (ST) 258, 11, 340, and 512, has
been shown to occur in European, US, and Israeli hospitals
and long-term care facilities [5].
The CPE situation varies dramatically in different parts of
the world, and also between European countries, from sporad-
ic occurrence to endemic situation [6, 7]. Regions and coun-
tries are known to be endemic for a certain carbapenemase, for
instance Klebsiella pneumoniae carbapenemase (KPC) in the
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USA, Puerto Rico, Colombia, Brazil, Argentina, Greece, and
Italy, New Delhi metallo-β-lactamase (NDM) in Indian sub-
continent, China, Bangladesh, and Pakistan, and oxacillinase-
48 (OXA-48) in Morocco, Turkey, and Malta [7].
CPE has been rare in Finland, as in the other Nordic coun-
tries [8]. Until 2013, the occurrence of CPE in Finland was
sporadic and related to traveling, and transmission of CPE
between two patients was suspected only once [9]. The first
outbreak of colonization with KPC-producing K. pneumoniae
(KPC-KP) strain ST512 affected nine patients in a primary
care hospital in 2013 [10]. A regional outbreak, in which a
KPC-KP ST512 strain spread from one hospital to four other
healthcare facilities occurred during 2013–2018 and caused
several clinical infections [11].
In this report, we present molecular epidemiology of CPE
in Finland during 2012–2018 and detailed characterization of
CPE strains causing clusters during the same time period.
Materials and methods
Surveillance and bacterial strains
In 2010, Finnish Institute for Health and Welfare (THL)
gave guidelines to clinical microbiology laboratories to
send CPE or carbapenem-resistant isolates for further char-
acterization. From 2016, on CPE surveillance in Finland is
based on communicable diseases act (1227/2016). All clin-
ical microbiology laboratories electronically notify
E. cloacae, E. coli, and K. pneumoniae isolates with re-
duced susceptibility to carbapenems to the National
Infectious Disease Registry and send bacterial strains with
carbapenemase gene to the Expert Microbiology Unit of
the THL. Clinical laboratories also send other CPE species
for further characterization. In addition to the patient’s
identity information and demographics, the laboratories
are requested to report specimen type (screening or clinical)
and information on the patient’s preceding travel or hospi-
talization history abroad if known. According to the nation-
al guidelines for controlling multidrug-resistant (MDR) mi-
crobes, patients who have been hospitalized abroad in the
preceding 12 months are placed on contact precautions up-
on admission and are screened for MDR bacteria, including
CPE [12]. For this work, one isolate per patient per species
per year was included, multiple isolates if the patient had
isolates with different carbapenemase genes or sequence
types (ST). Data on preceding hospitalization history
abroad were completed from the local infection control
nurses. Since 2015, all CPE isolates have routinely been
sequenced using whole genome sequencing (WGS) and
for this work, the older isolates (from years 2012 to 2014)
were sequenced retrospectively.
Phenotypic and molecular analysis
The species identification was performed in clinical laborato-
ries by matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry (VITEK MS,
bioMeriéux, Marcy-L’Etoile, France or Bruker Biotyper,
Becton, Dickinson and Company, New Jersey, USA), and
antimicrobial susceptibilities were assessed by disk diffusion
method or by gradient minimum inhibitory concentration
(MIC) determination test (Etest, bioMeriéux, Marcy-
L’Etoile, France) and interpreted according to clinical
breakpoints as published by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) versions
2.0-8.1, 2012-2018 [13]. Clinical laboratories use multiplex
real-time PCR or other molecular amplification techniques for
confirmation of carbapenemase genes in isolates with reduced
susceptibility to any carbapenem, as directed in The Finnish
national guideline [12]. National guideline screening
breakpoints for carbapenems are the same for E. coli,
E. cloacae, and K. pneumoniae as published in the
EUCAST guideline [14] except for meropenem for which
screening breakpoint is > 0.12 mg/L (zone diameter <
25 mm). For other Enterobacterales, the breakpoints are the
same as the EUCAST clinical breakpoints, ≥ 2 mg/L (zone
diameter ≤ 22 mm).
Several different commercial or in-house molecular ampli-
fication techniques have been used during the study period.
However, as based on the national guideline, these methods
detect at least blaKPC, blaNDM, blaOXA-48, and Verona
integron-encoded metallo-β-lactamase (blaVIM) genes [12].
WGSwas performed on aMiSeq instrument (Illumina, San
Diego, CA, USA) as previously described [11]. Analysis with
Trimmomatic (version 0.33), fastQC (version 0.11.6), SRST2
version 0.2.0, and SeqSphere+ (Ridom GmbH, Münster,
Germany) was accomplished as previously described [11].
Core genome (cg) MLST was performed to K. pneumoniae
and E. coli using available cgMLST scheme from Ridom and
C. freundii and K. oxytoca cgMLST schemes were made in
house having 2007 and 2947 targets, respectively. A cut-off of
10 allele differences was used to define clusters in cgMLST
analysis. This cut-off has been experimentally determined and
used in similar studies previously [11, 15]. WGS data from
each of the eight clusters are available from GenBank
(Table 1).
Results
In total, 231 CPE strains obtained from 202 patients during
2012–2018 were included in the study: 57% (115/202) were
from males and the median age of the patients was 56 years
(range, 6 months–98 years). Of the strains, 59% (137/231)
were found by screening, 32% (74/231) from clinical
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specimens, and for 9% (20/231) the information was not avail-
able. Of the clinical specimens, 42 (57%) were from urine, 8
(11%) from wound or abscess, 7 (9%) from blood, and 5 (7%)
from respiratory tract. Travel or hospitalization abroad was
reported in 91 patients and travel data was not available for
53 patients, 58 patients had no travel or hospitalization abroad.
The most common countries were India (n = 29 strains),
Greece (n = 11), Thailand (n = 9), Spain (n = 7), and Turkey
(n = 7). A total of 52 strains were imported after patient had
been hospitalized abroad: 10 in India, 7 in Greece, 5 in Egypt,
4 in Spain, 3 in Turkey, 3 in Russia, 3 more in Europe, 16
outside Europe, and in one case, the country was unknown
(Electronic Supplementary Material Table 1).
The annual number of CPE strains increased from 9 in 2012
to 70 in 2018 (Fig. 1), and the number of different STs increased
from 7 in 2012 to 33 in 2018 (Fig. 2). K. pneumoniae was the
dominant species during the study period, except for years 2016
and 2017 when E. coliwasmost common. E. cloacaewas found
consistently during the study period, and C. freundii only during
the last 4 years (2015–2018).
The most common CPE species were K. pneumoniae
(45%, 105/231), E. coli (40%, 92/231), C. freundii (6%, 14/
231), and E. cloacae (4%, 9/231) (Table 1). Most prevalent
carbapenemase genes were blaNDM-like (35%, 80/231),
blaOXA-48-like (33%, 76/231), and blaKPC-like (31%, 71/231).
Species where carbapenemase gene blaNDM-like was detected
commonly were E. coli (n = 50) and K. pneumoniae (n = 24),
blaOXA-48-like in E. coli (n = 39) and K. pneumoniae (n = 29),
and blaKPC-like in K. pneumoniae (n = 55) and C. freundii (n =
9). Of the individual carbapenemase genes, blaKPC-3 was the
most prevalent followed by blaOXA-48, blaNDM-5, and blaNDM-
1, respectively, and these were found in several different spe-
cies and STs. No plasmid mediated colistin resistance genes
were found.
K. pneumoniae had 23 different STs among 105 strains and
E. coli had 37 different STs among 92 strains. Among
K. pneumoniae, the most prevalent STs were ST512 (n =
39), ST258 (n = 8), ST11 (n = 7), and ST395 (n = 7) and
among E. coli, ST167 (n = 11), ST38 (n = 9), and ST405
(n = 9).
When the patient had travel or hospitalization history in a
European region, the most common carbapenemase genes
belonged to blaOXA-48-like (18/37), in South-East Asia,
Western Pacific, and Africa regions, it belonged to blaNDM-like
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Table 1 Clusters caused by carbapenemase-producing Enterobacterales in Finland, 2012–2018
Specimen type
Year(s) No. of
strains
No. of
patients
Species Gene Sequence
type
Screening Clinical Link abroad,
country
GenBank accession number of
strain belonging to cluster
2013 9 9 K. pneumoniae blaKPC-3 ST512 8 1 No SAMN14411195
2013–2018 26 23 K. pneumoniae blaKPC-3 ST512 4 10 No SAMN14411196
2015–2016 2 2 K. pneumoniae blaKPC-3 ST512 1 0 Hospital
transfer, Italy
SAMN14411197
2016–2018 8 8 C. freundii blaKPC-2 ST18 2 6 No SAMN14411198
2016–2018 3 3 K. pneumoniae blaKPC-3 ST11/NF* 2 1 Yes, Colombia SAMN14411199
2018 2 2 K. pneumoniae blaOXA-48 ST395 1 1 Hospitalization,
Russia
SAMN14411200
2018 2 2 K. pneumoniae blaOXA-48 ST307 2 0 No SAMN14411201
2018 2 2 K. pneumoniae blaOXA-48 ST273 1 1 No SAMN14411202
*For one strain completely identical STwas not found, there was one allele difference to ST11
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(34/40, 3/5, and 2/3 respectively), in Eastern Mediterranean
region, it belonged to bla
OXA-48-like
or blaNDM-like (10/16 and 7/16
respectively), and in Americas, it belonged to blaKPC-like (3/4).
Eight CPE clusters were detected during 2012–2018
(Table 1). The defined cut-off (10 allele differences) was used
except in one case: one C. freundii isolate with 14 allele dif-
ferences was defined belonging to the cluster since the patients
were hospitalized in the same healthcare facility less than
8 months apart. Five of eight clusters were caused by
K. pneumoniae st ra ins belonging to the CC258.
K. pneumoniae ST512 with blaKPC-3 gene caused three clus-
ters, two large ones with 9 and 23 patients, respectively and
one small with two patients. C. freundii ST18 with blaKPC-2
gene caused one cluster with 8 patients and K. pneumoniae
ST11 with blaKPC-3 gene one cluster with three patients.
Furthermore, there have been three small clusters caused by
K. pneumoniae strain having blaOXA-48 gene with different
STs. In two clusters, CPE was found more often in clinical
than in screening specimens and in four clusters, the first
specimen was obtained on clinical basis. In three clusters,
the link abroad was identified.
Discussion
Our study showed that CPE isolates are increasingly found in
Finland and have caused several clusters and outbreaks during
2013–2018. The first K. pneumoniae producing KPC-2 strain
was detected in Finland already in 2009 [16], and thereafter
KPC has become one of the most dominant carbapenemases
in Finland. KPC was common in K. pneumoniae and rare in
E. coli in our material which is in line with data reported from
Europe [8]. K. pneumoniae strains belonging to the clonal
complex (CC) 258 are wide spread [5], and it has been shown
that carbapenemase-producing K. pneumoniae strains are
more eager to spread than other strains [4]. Noteworthy, de-
spite that E. coliwas the most prevalent species during 2 years
of the study period and the second prevalent during the other
years, no carbapenemase-producing E. coli clusters were de-
tected in Finland. MLST results also showed that
K. pneumoniae had fewer STs than E. coli, indicating more
clonal population structure.
High number of C. freundii detected in our study was
related to the cluster with eight cases. Germany has de-
scribed one KPC-2 producing C. freundii outbreak with 6
cases [17]. These outbreaks indicate that also C. freundii
with KPC can cause outbreaks and be a reservoir of
CPE-genes.
We focused only on CPEs, we did not analyse carbapenem-
resistant Enterobacterales (CRE). It is possible that there were
CRE strains with carbapenemase genes that clinical laborato-
ries did not detect by the molecular methods they had in use.
However, based on the previous studies in Finland and other
European countries, other carbapenemase genes than those
recommended for testing in the national guideline are rare
[9, 18]. It is also possible that there were Enterobacterales
strains with carbapenemase genes which had MICs or inhibi-
tion zones for carbapenem antibiotic below screening
breakpoints. Especially OXA-48-like enzymes are weak
carbapenemases and the strains having blaOXA-48-like genes
can have very low carbapenem MICs. However, also these
kinds of strains seem to be very rare [8, 19, 20].
Simultaneously, as the number of strains increased annual-
ly, the number of different sequence types increased indicating
that importation from different foreign countries played a cru-
cial role in changing molecular epidemiology of CPE.
Endemicity of certain CPE-genes can be seen in our material
when examining travel destinations and hospitalization
abroad in relation to genes imported. Also, wide selection of
species, sequence types, and different CPE-genes detected
support the hypothesis that most cases are imported, although
direct links could not be found for all patients. The history of
traveling abroad is not systematically collected for all patients
admitted to Finnish healthcare facilities and this information
was missing for 53/202 patients. We cannot exclude possible
horizontal gene transfer between species, even though it
seems more improbable than clonal spread [4].
However, a worrisome phenomenon is that CPE was ini-
tially often found from clinical specimens and from patients
without direct link abroad indicating hidden local
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transmissions. This means that there are unknown CPE cases
and possible environmental sources challenging CPE control
measures. Alarming was also that after detecting a cluster and
in spite of infection control measures, onward transmission
was not always successfully controlled. One reason for this
might be that several Enterobacterales are known to survive
for long periods in the hospital environment [21]. Therefore,
we are currently updating national MDR control guidelines
concerning CPE, terminal cleaning, and screening strategies.
In conclusion, CPE findings in Finland are increasing but
still the majority are sporadic. The most common CPE so far
was K. pneumoniae with KPC-3 gene which caused most of
the CPE cases in outbreaks. Our CPE findings are similar to
those reported by other Nordic countries [22, 23].
Acknowledgements The authors wish to acknowledge all Finnish clini-
cal microbiology laboratories for participating, THL Expert
Microbiology laboratory for technical assistance, and CSC – IT Center
for Science, Finland, for providing computational resources.
Authors’ contributions K. Räisänen: whole genome sequencing, data
analysis, preparation of tables and figures, manuscript writing. O.
Lyytikäinen, J. Jalava: data analysis, manuscript writing. J. Kauranen,
E. Tarkka, B. Forsblom-Helander, J. O. Grönroos, R. Vuento: detection
and characterization of bacterial isolates and cluster/outbreak investiga-
tion. D. Arifulla, E. Sarvikivi, S. Toura: data collection, cluster
investigation.
Funding Information Open access funding provided byNational Institute
for Health and Welfare (THL).
Data availability The datasets generated during and/or analysed during
the current study are available from the corresponding author on reason-
able request.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethics approval Collection of CPE strains is based on the communica-
ble disease law. We do not contact patients, ethical permission is not
needed.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. WHO. Antimicrobial resistance, (2017), www.who.int/en/news-
room/fact-sheets/detail/antimicrobial-resistance
2. Perez F, Chakhtoura NGE, Papp-Wallace KM, Wilson BM,
Bonomo RA (2016) Treatment options for infections caused by
carbapenem-resistant Enterobacteriaceae: can we apply “precision
medicine” to antimicrobial chemotherapy? Expert Opin
Pharmacother 17:761–781. https://doi.org/10.1517/14656566.
2016.1145658
3. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS
(2014) Antibiotic treatment of infections due to carbapenem-resis-
tant Enterobacteriaceae: systematic evaluation of the available evi-
dence. Antimicrob Agents Chemother 58:654–663. https://doi.org/
10.1128/AAC.01222-13
4. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S,
Abudahab K, Goater R, Giani T, Errico G, AspburyM, Sjunnebo S,
Feil EJ, Rossolini GM, Aanensen DM, Grundmann H (2019)
Epidemic of carbapenem-resistant Klebsiella pneumoniae in
Europe is driven by nosocomial spread. Nat Microbiol. https://doi.
org/10.1038/s41564-019-0492-8
5. Pitout JDD, Nordmann P, Poirel L (2015) Carbapenemase-produc-
ing Klebsiella pneumoniae, a key pathogen set for global nosoco-
mial dominance. Antimicrob Agents Chemother 59:5873–5884.
https://doi.org/10.1128/AAC.01019-15
6. Brolund A, Lagerqvist N, Byfors S, Struelens MJ, Monnet DL,
Albiger B, Kohlenberg A (2019) Worsening epidemiological situ-
ation of carbapenemase-producing Enterobacteriaceae in Europe,
assessment by national experts from 37 countries, July 2018.
Euro Surveill 24. https://doi.org/10.2807/1560-7917.ES.2019.24.
9.1900123
7. Logan LK WR (2017) The epidemiology of carbapenem-resistant
Enterobacteriaceae: the impact and evolution of a global menace. J
Infect Dis 215:28–36. doi: https://doi.org/10.1093/infdis/jiw282
8. Grundmann H, Glasner C, Albiger B et al (2016) Occurrence of
carbapenemase-producing Klebsiella pneumoniae and Escherichia
coli in the European survey of carbapenemase-producing
Enterobacteriaceae (EuSCAPE): a prospective, multinational study.
Lancet Infect Dis 17:153–163. https://doi.org/10.1016/S1473-
3099(16)30257-2
9. ÖsterbladM, Kirveskari J, Hakanen AJ, Tissari P, VaaraM, Jalava J
(2012) Carbapenemase-producing Enterobacteriaceae in Finland:
the first years (2008-11). J Antimicrob Chemother 67:2860–2864.
https://doi.org/10.1093/jac/dks299
10. Kanerva M, Skogberg K, Ryynänen K, Pahkamäki A, Jalava J,
Ollgren J, Tarkka E, Lyytikäinen O (2015) Coincidental detection
of the first outbreak of carbapenemase-producing Klebsiella
pneumoniae colonisation in a primary care hospital, Finland,
2013. Euro Surveill 20:21172. https://doi.org/10.2807/1560-7917.
ES2015.20.26.21172
11. van Beek J, Räisänen K, Broas M et al (2019) Tracing local and
regional clusters of carbapenemase- producing Klebsiella
pneumoniae ST512 with whole genome sequencing, Finland,
2013 to 2018. Euro Surveill 24. https://doi.org/10.2807/1560-
7917.ES.2019.24.38.1800522
12. Kolho E, Lyytikäinen O, Jalava J Ohje moniresistenttien mikrobien
tartunnantorjunnasta. [National guideline for control of multidrug-
resistant microbes]. Helsinki: National Institute for Health and
Welfare (THL); 2017. Finnish. In: http://urn.fi/URN:ISBN:978-
952-302-943-9
1655Eur J Clin Microbiol Infect Dis (2020) 39:1651–1656
13. The European Committee on Antimicrobial Susceptibility Testing.
Breakpoint tables for interpretation of MICs and zone diameters.
Version 2.0–8.1, 2012–2018. https://www.eucast.org
14. Giske GC, Martinez-Martinez L, Cantón R, Stefani S, Skov R,
Glupczynski Y, Nordmann P, Wootton M, Miriagou V, Simonsen
SG, Zemlickova H, Cohen-Stuart J, Gniadkowski M (2017)
EUCAST guidelines for detection of resistance mechanisms and
specific resistances of clinical and/or epidemiological importance
15. Kluytmans-van den BerghMFQ, Rossen JWA,Bruijning-Verhagen
PCJ, Bonten MJM, Frieich AW, Vandenbroucke-Grauls CMJE,
Willems RJL, Kluytmans JAJW (2016) Whole-genome multilocus
sequence typing of extended-spectrum-beta-lactamase-producing
Enterobacteriaceae. J Clin Microbiol 54:2919–2927. https://doi.
org/10.1128/JCM.01648-16
16. Österblad M, Kirveskari J, Koskela S, Tissari P, Vuorenoja K,
Hakanen AJ, Vaara M, Jalava J (2009) First isolations of KPC-2-
carrying ST258 Klebsiella pneumoniae strains in Finland, June and
August 2009. Euro Surveill 14
17. Schweizer C, Bischoff P, Bender J, Kola A, Gastmeier P, Hummel
M, Klefisch F, Schoenrath F, Frühauf A, Pfeifer Y (2019) Plasmid-
media ted t ransmiss ion of KPC-2 carbapenemase in
Enterobacteriaceae in critically ill patients. Front Microbiol 10:
276. https://doi.org/10.3389/fmicb.2019.00276
18. Trepanier P, Mallard K, Meunier D et al (2017) Carbapenemase-
producing Enterobacteriaceae in the UK: a national study
(EuSCAPE-UK) on prevalence, incidence, laboratory detection
methods and infection control measures. J Antimicrob Chemother
72:596–603. https://doi.org/10.1093/jac/dkw414
19. Woodford N, Xu-McCrae L, Mushtaq S, Wu HHT, Ellington MJ,
Lancaster O, Davies F, Donaldson H, Rao GG, Verma A,Wareham
DW, Ciesielczuk H, Stone GG, Irani PM, Bracher S, Hawkey PM
(2018) Prevalence of carbapenem resistance and carbapenemase
production among Enterobacteriaceae isolated from urine in the
UK: results of the UK infection-Carbapenem Resistance
Evaluation Surveillance Trial (iCREST-UK). J Antimicrob
Chemother 73:698–702. https://doi.org/10.1093/jac/dkx471
20. Fattouh R, Tijet N, McGeer A, Poutanen SM,Melano RG, Patel SN
(2015) What is the appropriate meropenem MIC for screening of
carbapenemase-producing Enterobacteriaceae in low-prevalence
settings? Antimicrob Agents Chemother 60:1556–1559. https://
doi.org/10.1128/AAC.02304-15
21. Smismans A, Ho E, Daniels D, Ombelet S, Mellaerts B, Obbels D,
Valgaeren H, Goovaerts A, Huybrechts E, Montag I, Frans J (2019)
New environmental reservoir of CPE in hospitals. Lancet Infect Dis
19:580–581. https://doi.org/10.1016/S1473-3099(19)30230-0
22. Löfmark S, Sjöström K, Mäkitalo B, Edquist P, Wisell KT, Giske
CG (2015) Carbapenemase-producing Enterobacteriaceae in
Sweden 2007–2013: experiences from seven years of systematic
surveillance and mandatory reporting. Drug Resist Updat 20:29–
38. https://doi.org/10.1016/j.drup.2015.05.001
23. Samuelsen Ø, Overballe-Petersen S, Bjørnholt JV, Brisse S,
Doumith M, Woodford N, Hopkins KL, Aasnæs B, Haldorsen B,
Sundsfjord A, on behalf of The Norwegian Study Group on, CPE
(2017) Molecular and epidemiological characterization of
carbapenemase-producing Enterobacteriaceae in Norway, 2007 to
2014. PLoS One 12:e0187832. https://doi.org/10.1371/journal.
pone.0187832
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
1656 Eur J Clin Microbiol Infect Dis (2020) 39:1651–1656
